|
Daily Medical Update
Nephrolithiasis
Thursday, May 28, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
The Journal of urology (2025) - Practice Guideline
Key Findings
- Treatment selection is guided by patient factors, urinary tract anatomy, and stone characteristics to improve patient outcomes.
- Shared decision-making that incorporates patient goals, resource availability, and physician expertise is emphasized to improve treatment decisions.
📋 Practice Implication: Use the updated AUA framework to tighten initial imaging, referral, and medical expulsive therapy decisions before procedural escalation.
|
The Journal of urology (2025) - Practice Guideline
Key Findings
- Procedure choice is linked to patient factors, anatomy, and stone characteristics to improve surgical outcomes across adult and pediatric scenarios.
- The guideline supports selecting techniques, technologies, and medications that improve patient outcomes rather than relying on a single default approach.
📋 Practice Implication: Counsel patients that ESWL, ureteroscopy, and PCNL are not interchangeable and that stone size, location, and anatomy should drive urology referrals.
|
The Journal of urology (2025) - Practice Guideline
Key Findings
- Optimal treatment modality selection is individualized to improve outcomes by aligning intervention choice with anatomy, stone features, and patient priorities.
- The guideline extends outcome-focused decision-making to advanced surgical care and future treatment pathways intended to improve longer-term management.
📋 Practice Implication: For recurrent or complex stone disease, revisit long-term prevention and advanced procedural planning instead of treating each episode as an isolated event.
|
Minerva urology and nephrology (2025) - Systematic Review
Key Findings
- Thiazide therapy reduced recurrent nephrolithiasis versus placebo (RR 0.63; 95% CI 0.49-0.83; P=0.0007) in hypercalciuric patients.
- Twenty-four-hour urinary calcium decreased with thiazides (MD -40.59; 95% CI -76.39 to -4.79), while 24-hour citraturia showed no significant difference versus placebo.
📋 Practice Implication: In recurrent calcium oxalate stone formers with hypercalciuria, thiazides remain a reasonable preventive option when paired with metabolic monitoring.
|
World journal of urology (2025) - Systematic Review
Key Findings
- Compared with placebo, chlorthalidone 50 mg/d (OR 0.18; 95% CI 0.04-0.88), hydrochlorothiazide 50 mg/d (OR 0.52; 95% CI 0.29-0.93), and trichlormethiazide 4 mg/d (OR 0.26; 95% CI 0.10-0.68) lowered kidney stone recurrence.
- No dose-dependent benefit was shown for lower-dose hydrochlorothiazide or chlorthalidone, and trichlormethiazide 4 mg/d increased adverse effects versus placebo (OR 49.96; 95% CI 1.78-1402.80).
📋 Practice Implication: Do not treat thiazide prophylaxis as a class effect; if prescribing, discuss the limited evidence base, regimen-specific benefit, and adverse-effect tradeoffs.
|
|
💡
Summary
Recent nephrolithiasis literature is led by the 2026 AUA surgical guideline series, which emphasizes matching imaging, medical expulsive therapy, and procedural choice to stone burden, anatomy, patient goals, and available expertise to improve outcomes. Two updated thiazide syntheses also sharpen recurrence prevention decisions: one pooled analysis found lower calcium oxalate stone recurrence with thiazides in hypercalciuria, while a network meta-analysis argued that benefit is regimen-specific and current evidence is too limited to justify routine indiscriminate prescribing.
|
|